# CHAIN Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chain-biotechnology

- Industry: Biotechnology
- Headquarters: Marlow, UK
- Website: www.chainbiotech.com
- Latest round: Seed (Jan 1, 2015)
- Investors on record: 2

## About

CHAIN Biotechnology Limited focuses on developing innovative oral vaccines and immuno-therapies targeting the lower gastrointestinal tract, utilizing proprietary technology to enhance therapeutic delivery and efficacy.Founded in 2014 in Marlow, UK, CHAIN Biotechnology Limited specializes in the creation of oral vaccines and therapies for gastrointestinal disorders. The company was co-founded by Basil Omar and Edward Green, with Matthew Duchars as CEO. CHAIN Biotechnology raised Seed funding in January 2015, led by UK Innovation & Science Seed Fund and Rockley Group, marking its initial entry into the funding landscape.CHAIN Biotechnology specializes in the development of innovative oral vaccines and immuno-therapies aimed at the lower gastrointestinal tract. Utilizing their proprietary Clostridium Assisted Drug Delivery (CADD™) platform, the company employs a specific strain of Clostridium to deliver therapeutic payloads directly to the gut. This method leads to the production of live biotherapeutic products that engage the mucosal immune system, offering targeted treatment for various gastrointestinal disorders. The products primarily serve clients in North America and Europe, including clinical research institutions and pharmaceutical companies.CHAIN Biotechnology's revenue model relies on partnerships and collaborations with pharmaceutical firms and research institutions, which typically involve licensing agreements for their CADD™ platform and co-development arrangements. These transactions are structured around B2B engagements that yield milestone payments and royalties from successful product commercialization. While specific revenue figures are not disclosed, the focus on high-value therapeutic development indicates a robust revenue generation framework tailored to healthcare sector needs.In 2015, CHAIN Biotechnology Limited raised Seed funding, the proceeds of which are expected to support the development of new products targeting gastrointestinal disorders. The company is actively working on expanding its market presence in North America and Europe, aiming to enhance its portfolio of oral vaccines and immuno-therapies. This strategic focus aligns with their goal to address unmet medical needs in these regions, leveraging their proprietary technology to facilitate innovative solutions for healthcare challenges.

## Funding rounds

- Seed, Jan 1, 2015 — Rockley Group, UK Innovation & Science Seed Fund

## Investors

- Rockley Group (https://capitalatlas.ai/funds/rockley-group) — Seed
- UK Innovation & Science Seed Fund (https://capitalatlas.ai/funds/uk-innovation-science-seed-fund) — Seed